Arcturus Therapeutics (ARCT) Set to Announce Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Arcturus Therapeutics to post earnings of ($0.70) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million during the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the prior year, the company earned ($1.98) earnings per share. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Stock Performance

Shares of ARCT traded up $0.09 during mid-day trading on Tuesday, hitting $17.91. 199,073 shares of the stock were exchanged, compared to its average volume of 465,359. The company has a market cap of $482.32 million, a PE ratio of -6.77 and a beta of 2.64. Arcturus Therapeutics has a 52-week low of $17.26 and a 52-week high of $45.00. The firm has a 50-day moving average of $20.78 and a two-hundred day moving average of $24.44.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ARCT. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.